comparemela.com

Latest Breaking News On - Protein degrader optimizer - Page 1 : comparemela.com

Needle Tracking System Market: Ensuring Accuracy and Driving

Nuclear Pharmacy Market: Delivering Targeted Therapies

Stifel Upgrades C4 Therapeutics to Buy From Hold, Raises Price Target to $12 From $2

C4 Therapeutics has an average rating of outperform and price targets ranging from $1 to $84, according to analysts polled by Capital IQ. Price: 2.84, Change: +0.5, Percent Change: +21.37 .

Top Midday Gainers

C4 Therapeutics shares more than doubled amid heavy trading after the company said late Tuesday that clinical data from an ongoing trial of CFT7455 for the potential treatment of multiple myeloma.

Top Premarket Gainers

C4 Therapeutics surged 59% premarket on Tuesday, following a license and research collaboration agreement with Merck to develop degrader-antibody conjugates. Icosavax shares soared 47%,.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.